Press Release:
Press Release
News Article February 2005
BURLINGTON, Mass., Feb. 9 /PRNewswire/ -- LeMaitre Vascular today acquired Endomed, Inc., a maker of endovascular stent grafts for the minimally invasive treatment of thoracic and abdominal aortic aneurysms. Endomed's products are CE marked and have been sold in Europe and other international markets since 2002.
Endomed's products allow surgeons to treat aortic aneurysms through a small incision in the leg rather than through invasive open surgery of the thorax or abdomen. Endomed is one of only a limited number of companies in the world with a CE-marked stent graft for the treatment of disease in the thoracic aorta. Endomed's aorto-uni-iliac stent graft is in a Phase I clinical trial in the United States. Endomed's products are protected by a comprehensive portfolio of U.S. and foreign patents.
'Vascular medicine is moving toward minimally invasive repair at a rapid pace,' said George W. LeMaitre, Chairman, President, & CEO. 'We are pleased to be part of the endovascular revolution. When cutting edge technology improves patient care, everyone benefits.'
Endomed was founded and majority owned by Edward Diethrich, M.D., founder of the Arizona Heart Institute and Chief of Cardiovascular Surgery at the Arizona Heart Hospital.
Financial terms of the acquisition were undisclosed. The acquisition was funded by debt provided by Brown Brothers Harriman.
Founded in 1983, LeMaitre is a privately held vascular device company headquartered in Burlington, Massachusetts. LeMaitre designs, manufactures and markets vascular surgery devices. LeMaitre has manufacturing facilities in Burlington (MA), St. Petersburg (FL) & Brymbo (UK) and international headquarters in Frankfurt (Germany).
This press release is provided in good-faith by Chiltern Magazine Services Ltd ("CMS") as a service to users of www.telecomsinfo.com. Whilst all care is taken in sourcing and preparing material includede here, any error or incorrect content cannot form the basis for any legal action against the site-owner. Users are advised to check the accuracy of any statements before relying upon them. Likewise, any forward-looking statements made by the author of the press release should be treated as such.
CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UKTel: +44 (0)1494 771734
Fax: +44 (0)1494 778994
e-mail: Editor, CMSinfo
copyright © 2008 all rights reserved
For more information about us, visit CMSinfo.
